Growth Prospects of the Renal Cell Carcinoma - Pipeline Review, H2 2016
Renal Cell Carcinoma - Pipeline Review, H2 2016 is a new market research publication announced by Reportstack. This report provides an overview of the Renal Cell Carcinoma (Oncology) pipeline landscape.
Renal cell carcinoma (RCC, formerly known as hypernephroma) is a kidney cancer that originates in the lining of the proximal convoluted tubule. Symptoms include hematuria, loin pain, abdominal mass, malaise, which is a general feeling of feeling unwell, weight loss and/or loss of appetite, anemia resulting from depression of erythropoietin and erythrocytosis. The predisposing factors are age and hereditary factors. The disease is controlled by chemotherapy and radiation therapy.
To access full report with TOC, please visit Renal Cell Carcinoma - Pipeline Review, H2 2016
Report Highlights
The Pharmaceutical and Healthcare latest pipeline guide Renal Cell Carcinoma – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Renal Cell Carcinoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Renal Cell Carcinoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Renal Cell Carcinoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 13, 46, 42, 3, 34, 4 and 2 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 5, 3 and 4 molecules, respectively.Renal Cell Carcinoma.
Renal Cell Carcinoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Renal Cell Carcinoma (Oncology).
- The pipeline guide reviews pipeline therapeutics for Renal Cell Carcinoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Renal Cell Carcinoma (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Renal Cell Carcinoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Renal Cell Carcinoma (Oncology)
- The pipeline guide reviews pipeline therapeutics for Renal Cell Carcinoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Renal Cell Carcinoma (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Renal Cell Carcinoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Renal Cell Carcinoma (Oncology)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Renal Cell Carcinoma (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Renal Cell Carcinoma (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Renal Cell Carcinoma (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Renal Cell Carcinoma (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Companies Mentioned
AbbVie Inc Acceleron Pharma, Inc. Advenchen Laboratories, LLC Altor BioScience Corporation Ambrx, Inc. Amgen Inc. Ampio Pharmaceuticals, Inc. Apac Biotech Pvt Ltd arGEN-X BV Argos Therapeutics, Inc. ARMO Biosciences, Inc. Arrowhead Pharmaceuticals, Inc. Astellas Pharma Inc. Bayer AG Bio-Cancer Treatment International Limited BIOCAD Bionomics Limited Bionovis SA Boehringer Ingelheim GmbH Boston Biomedical, Inc. Bristol-Myers Squibb Company Calithera Biosciences, Inc. Cellceutix Corporation Celldex Therapeutics, Inc. Chipscreen Biosciences Ltd Cytune Pharma SAS Dr. Reddy's Laboratories Limited EirGenix Inc. Eisai Co., Ltd. Eli Lilly and Company Exelixis, Inc. F. Hoffmann-La Roche Ltd. Five Prime Therapeutics Inc Gene Techno Science Co., Ltd. Genor BioPharma Co Ltd GlaxoSmithKline Plc Hemispherx Biopharma, Inc. Horizon Pharma Plc Hutchison MediPharma Limited Immatics Biotechnologies GmbH Immune Design Corp. Immunicum AB ImmunoGen, Inc. Immunomedics, Inc. Incuron, LLC Incyte Corporation Inspyr Therapeutics Inc Johnson & Johnson KAHR medical Ltd. Karyopharm Therapeutics, Inc. KineMed, Inc. Kyowa Hakko Kirin Co., Ltd. Lead Discovery Center GmbH Mabion SA MacroGenics, Inc. MedImmune LLC Medivation, Inc. Merck & Co., Inc. Merck KGaA Millennium Pharmaceuticals Inc Molecular Partners AG Mologen AG Monopar Therapeutics LLC Mycenax Biotech Inc. Nektar Therapeutics NewLink Genetics Corporation Novartis AG NovaTarg Therapeutics, Inc Omeros Corporation Oncobiologics, Inc. OncoMax Ono Pharmaceutical Co., Ltd. Peloton Therapeutics, Inc. Pfizer Inc. Pharmacyclics Inc Prima BioMed Ltd. PsiOxus Therapeutics Limited Rexahn Pharmaceuticals, Inc. Richter Gedeon Nyrt. Sevion Therapeutics, Inc. Sillajen Biotherapeutics Sorrento Therapeutics Inc Sumitomo Dainippon Pharma Co Ltd Syndax Pharmaceuticals Inc Taiwan Liposome Company, Ltd. Takeda Pharmaceutical Company Limited Tara Immuno-Oncology Therapeutics LLC TC BioPharm Limited Theravectys SA Tocagen Inc. TRACON Pharmaceuticals Inc TVAX Biomedical, Inc. Tyrogenex, Inc. Vascular Biogenics Ltd. X4 Pharmaceuticals, Inc.
Contact:
Debora White
Manager - Marketing
Ph: +1-888-789-6604
Reportstack Market Research
###
posted by Reportstack @ 23:46
0 Comments
0 Comments:
Post a Comment
Subscribe to Post Comments [Atom]
<< Home